FDA Inspection 1211639 — Sami Ibrahimi, M.D.
The FDA completed an inspection of Sami Ibrahimi, M.D. on Jul 14, 2023 in Oklahoma City, OK. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jul 14, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Oklahoma City, OK (United States)
Additional details
Clinical Investigator (CI)